Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 1.00 |
| ▸ | NPC1 | O15118 | 7/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | WDR5 | P61964 | 2/20 | 0.63 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.63 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lansoprazole Sulfide SCHEMBL30053816 | 1.00 | RAB9A (1.00) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL6948284 | 0.99 | RAB9A (0.98) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL1680900 | 0.99 | RAB9A (0.98) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL1681186 | 0.99 | RAB9A (0.98) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL1681462 | 0.95 | RAB9A (0.90) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Lansoprazole Sulfide SCHEMBL8184520 | 0.94 | RAB9A (0.89) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL29323856 | 0.93 | RAB9A (0.86) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6440543 | 0.92 | RAB9A (0.85) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Water SCHEMBL6737292 | 0.91 | RAB9A (0.83) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| Water SCHEMBL6737289 | 0.91 | RAB9A (0.83) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163419-A | Preparation method of lansoprazole | 辰欣药业股份有限公司 | 2022-03-11 | — | — | CN | claimed |
| CN-111714639-A | Composition comprising histamine release-promoting substance and benzimidazole derivative | 黄泳华 | 2020-09-29 | — | — | CN | claimed |
| CN-111084886-A | Composition comprising fatty acid or derivative thereof and benzimidazole derivative | 黄泳华 | 2020-05-01 | — | — | CN | claimed |
| US-9228216-B2 | Synthesis of prazole compounds | CODEXIS, INC. (US) | 2016-01-05 | — | — | US | claimed |
| US-20150056668-A1 | SYNTHESIS OF PRAZOLE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-02-26 | — | — | US | claimed |
| US-20130012714-A1 | NOVEL SOLVATE OF DEXLANSOPRAZOLE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-01-10 | — | — | US | claimed |
| EP-2510089-A2 | SYNTHESIS OF PRAZOLE COMPOUNDS | Codexis, Inc. (US) | 2012-10-17 | — | — | EP | claimed |
| US-8039631-B2 | Process for preparing crystalline form A of Lansoprazole | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2011-10-18 | — | — | US | claimed |
| WO-2011098938-A1 | NOVEL SOLVATE OF DEXLANSOPRAZOLE | ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2011-08-18 | — | — | WO | claimed |
| WO-2011071982-A2 | SYNTHESIS OF PRAZOLE COMPOUNDS | CODEXIS, INC. (US) | 2011-06-16 | — | — | WO | claimed |
| US-6603009-B2 | Oxidation of a thioether to a sulfoxide using sodium percarbonate and a molybdenum salt as catalyst; making lansoprazole, omeprazole, rabeprazole, and pantoprazole | ESTEVE QUIMICA, S.A. (ES) | 2003-08-05 | — | — | US | claimed |
| US-20030028030-A1 | Method for oxidizing a thioether group into a sulfoxide group | ESTEVE QUIMICA, S.A. (ES) | 2003-02-06 | — | — | US | claimed |
| EP-1270555-A1 | METHOD FOR OXIDIZING A THIOETHER GROUP INTO A SULFOXIDE GROUP | ESTEVE QUIMICA, S.A. (ES) | 2003-01-02 | — | — | EP | claimed |
| WO-2000078729-A1 | CRYSTALLINE FORMS OF LANSOPRAZOLE | INSTYTUT FARMACEUTYCZNY (PL) | 2000-12-28 | — | — | WO | claimed |
| WO-2000027841-A1 | METHOD OF PREPARING SULFIDE DERIVATIVES | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2000-05-18 | — | — | WO | claimed |
| US-5578732-A | MONO-OXIDATION OF SULFUR ATOM BY HYDROGEN PEROXIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-11-26 | — | — | US | claimed |
| EP-0382489-B1 | Use of benzimidazole derivatives as antibacterial agents | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-11-17 | — | — | EP | claimed |
| US-5013743-A | Use of substituted pyridylmethylsulfinyl- and pyridylmethylthiobenzimidazoles such as lansoprazole, 2-(3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl)methylthiobenzimidazole | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-05-07 | — | — | US | claimed |
| EP-0382489-A2 | Use of benzimidazole derivatives as antibacterial agents | Takeda Chemical Industries, Ltd. (JP) | 1990-08-16 | — | — | EP | claimed |
| US-4628098-A | Including Prevacid (TM) lansoprazole, 2-(3-methyl-4-(2,2,2-trifluoroethoxy)-5-methyl-pyrid-2 -yl)methylsulfinylbenzimidazole; proton pump inhibitors, antiulcer, antisecretory agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-12-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030028030-A1 | Method for oxidizing a thioether group into a sulfoxide group | CBR1, CBR3, SCO2 | RAB9A 2297/4885NPC1 1435/4885CYP1A2 2157/4885 |
| US-20130012714-A1 | NOVEL SOLVATE OF DEXLANSOPRAZOLE | CYP2D6, CYP2S1, CYP2F1 | RAB9A 1039/4885NPC1 4592/4885CYP1A2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.